Compare PFGC & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFGC | DVA |
|---|---|---|
| Founded | 1885 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 13.5B |
| IPO Year | 2014 | 2003 |
| Metric | PFGC | DVA |
|---|---|---|
| Price | $109.48 | $214.33 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $116.44 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.4M | 660.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.26 | ★ 2.87 |
| Revenue | ★ $17,619,900,000.00 | $13,643,069,000.00 |
| Revenue This Year | $15.14 | $3.85 |
| Revenue Next Year | $6.61 | $3.07 |
| P/E Ratio | $85.04 | ★ $74.31 |
| Revenue Growth | 5.12 | ★ 6.46 |
| 52 Week Low | $80.82 | $101.00 |
| 52 Week High | $109.05 | $215.33 |
| Indicator | PFGC | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 76.07 | 72.97 |
| Support Level | $91.78 | $189.09 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.63 | 5.18 |
| MACD | 0.49 | 0.17 |
| Stochastic Oscillator | 99.11 | 98.21 |
Performance Food Group Co , markets and distributes national and company-branded food and food-related products. The company also specializes in distributing candy, snacks, beverages, cigarettes, other tobacco products, health and beauty care products and other items to vending distributors, box retailers, theaters, convenience stores, drug stores, grocery stores, travel providers, and hospitality providers. The company has three reportable segments: Foodservice, Vistar, and Convenience.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.